Acetic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Acetic Acid: From Otitis Externa to Post-Bacterial Disorder
One-Sentence Summary
Acetic acid is a topical acidifying antiseptic, originally used for otitis externa and external ear disease. The TxGNN model predicts it may be effective for post-bacterial disorder, but no clinical trials and no publications currently support this prediction. The top-ranked predictions are computational only. The most biologically plausible lead among the candidates is tinea corporis (rank 9), which has indirect, mostly historical literature support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Otitis externa; external ear disease (the Canadian licence records list no indication text) |
| Predicted New Indication | Post-bacterial disorder |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, acetic acid is a topical antiseptic and acidifier with antibacterial activity. Its use in otitis externa is consistent with lowering local pH and inhibiting microbial growth.
For the top prediction, post-bacterial disorder, no plausible mechanism is apparent. Post-infectious conditions are typically immune-mediated rather than ongoing infections, so a topical antiseptic is unlikely to address them. The same holds for the other high-scoring predictions: postinfectious vasculitis, post-infectious syndrome, Chagas cardiomyopathy, infection-related hemolytic uremic syndrome and drug-induced osteoporosis. All have TxGNN scores of 0.9967 or higher, but the scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Two lower-ranked candidates have a loose mechanistic rationale:
- Infective urethral stricture (rank 5): dilute acetic acid is used as an irrigant in other settings, but the condition is fibrotic and structural, and no data support benefit.
- Tinea corporis (rank 9, score 0.9925): acidification of the skin and disruption of fungal cell membranes could plausibly give antifungal activity. Historical reports describe dilute acetic acid for related dermatophyte infections (see below). This is the only candidate with an evidence level above L5 (L4), and it is best viewed as a research question rather than a validated indication.
Clinical Trial Evidence
Currently no related clinical trials registered for the top prediction (post-bacterial disorder), nor for tinea corporis or any other predicted indication.
Literature Evidence
No literature is available for the top prediction, post-bacterial disorder. The only publications retrieved for the top predictions relate to rank 3 (post-infectious syndrome) and rank 9 (tinea corporis). The most relevant are shown below.
Tinea corporis (rank 9)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20256868 | 1947 | Historical case series | The Urologic and Cutaneous Review | Larger series of tinea capitis patients treated with special iodine and dilute acetic acid; no abstract available |
| 20996178 | 1946 | Historical clinical report | JAMA | Tinea capitis treated with special iodine and dilute acetic acid; no abstract available |
| 20983383 | 1946 | Historical clinical report | Archives of Dermatology and Syphilology | Same approach in tinea capitis; no abstract available |
| 13616002 | 1958 | Historical clinical report | Vestnik Dermatologii i Venerologii | Foot epidermophytosis treated with increasing concentrations of acetic acid; no abstract available |
| 31049344 | 2019 | Clinical report | Skin Appendage Disorders | Chemical peeling as an alternative to oral antifungals for onychomycosis in elderly and diabetic patients |
| 26857689 | 2016 | In vitro study | Mycoses | Topical antifungal products compared in an in vitro onychomycosis model against Trichophyton mentagrophytes |
| 16233325 | 2002 | In vitro study (indirect) | J Biosci Bioeng | Fermented herb product inhibited dermatophytes under low-pH conditions; organic acids implicated |
| 33625606 | 2021 | In vitro study (indirect) | World J Microbiol Biotechnol | Lactic acid bacteria strain inhibited Trichophyton rubrum growth |
| 37256034 | 2023 | Case series (safety) | Archives of Plastic Surgery | Burns caused by Korean folk remedies, a warning about uncontrolled acid use |
Post-infectious syndrome (rank 3)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20848144 | 2011 | Systematic review | J Gastroenterol | Reviews animal models of post-infectious IBS. It does not test acetic acid as a treatment, so it is not efficacy evidence |
These studies are old, uncontrolled, in vitro, or indirect. None directly tests acetic acid in tinea corporis.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02254085 | ACID CONCENTRATE A1230 | Not listed | Not listed |
| 02415496 | SELECTBAG ONE (AX 2525 G) | Not listed | Not listed |
| 02414902 | SELECTBAG ONE (AX 325 G) | Not listed | Not listed |
| 02415461 | SELECTBAG ONE (AX 250 G) | Not listed | Not listed |
| 02414821 | SELECTBAG ONE (AX 150 G) | Not listed | Not listed |
There are 20 valid single-ingredient licences in total. The product names (acid concentrates and dialysis-related bags) suggest that the Canadian licences are mainly dialysis concentrates rather than ear preparations, so the licensed products may not match the original ear indication or a topical route.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): inherited porphyria, porphyrin metabolism disease, porphyria, herpes simplex infection, geniculate herpes zoster.
- Tolerability signal: a 2023 case series reported burns from folk remedies, so uncontrolled use of acids on skin carries a risk of chemical injury.
- Systemic exposure: systemic acid exposure is a safety concern for the systemic or deep-tissue conditions among the predictions (e.g. Chagas cardiomyopathy, hemolytic uremic syndrome).
No drug-interaction records were found. Please refer to the package insert for label warnings and contraindications, which are not yet available for review.
Conclusion and Next Steps
Decision: Hold
Rationale: The top predictions have high model scores but no trials, no publications, and no plausible mechanism, so they rest on computation alone (L5). Tinea corporis is the only candidate with indirect support (L4), but that support comes from historical, uncontrolled or in vitro studies. Label safety data are also missing.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which block safety screening
- Mechanism of action data for acetic acid
- Confirmation of which licensed Canadian products are relevant, and their routes and dosage forms
- For tinea corporis: in vitro susceptibility testing against dermatophytes, then a modern controlled trial with defined concentrations and skin-tolerability monitoring
- Deprioritising the immune-mediated and systemic predictions unless a mechanistic rationale emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.